Conference Call Notification
Cardiome will hold a teleconference and webcast on Tuesday, May 13, 2008 at 4:30pm Eastern (1:30pm Pacific). To access the conference call, please dial 416-641-6117 or 866-299-6655. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome's website at http://www.cardiome.com.
Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through June 13, 2008. Please dial 416-695-5800 or 800-408-3053 and enter code 3261188 followed by the number sign to access the replay.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.
Vernakalant (iv) is the intravenous formulation of an investigational
drug being evaluated for the acute conversion of atrial fibrillation.
Positive top-line results from two pivotal Phase 3 trials for vernakalant
(iv), called ACT 1 and ACT 3, were released in December 2004 and September
2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted
a New Drug Application for vernakalant (iv) in December 2006. Positive
top-line results from an additional Phase 3 study evaluating patients with
post-operative atrial arrhythmia, called ACT 2, were released in June 2007.
An open-la
'/>"/>
| SOURCE Cardiome Pharma Corp. Copyright©2008 PR Newswire. All rights reserved |